ArticleAmerican journal of cancer research2025
The clinicopathological features, treatment patterns, and prognosis of trichilemmal carcinoma: a retrospective case-series study.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichilemmal carcinoma (TC) is a rare malignant cutaneous appendage neoplasm originating from the epithelium of the outer root sheath of hair follicles. TC is generally non-invasive, causing only localized damage, and can be successfully managed with wide excision. Although recurrence and metastasis are rare, such cases often exhibit high malignancy, necessitating regular follow-up. Here, a retrospective study was conducted to review the clinical and histopathological features, diagnosis, and treatment of TC. Seven TC patients were enrolled in this study with 3 female and 4 male patients. The average age was 56.14±20.72 years old and the average year of lesion onset to clinic visit was 3.91±5.07 years. All patients received enlarged excision therapy. Six of Seven patients were followed for at least two years. Only one reported lesion relapse one year after surgery with 0.5 cm enlarged margin. In conclusion, surgery is a great method for TC treatment with at least 1 cm margin. Long-term post operative follow-up is necessary to screening recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.